Free tool
Cell therapy stocks
We cover 4 companies grouped under the Cell therapy theme. The median market value in the group is $3.04B. Across the group, the median move over the past trading day is +2.61%. Price change over the past year runs from −28.1% to +166.3% across the middle 80 percent of the group, with a median of +2.8%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $4.14B | Mid cap | −38.44% | Nov 11, 2026 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.82B | Mid cap | +233.60% | Nov 5, 2026 |
| MSB.AX | Mesoblast Limited | $2.25B | Mid cap | −3.82% | Aug 27, 2026 |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +9.42% | Aug 27, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.